This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Articles

Introduction: Using the Newer Pharmacotherapeutic Agents as Mood Stabilizers in Bipolar Spectrum Disorders

K. N. Roy Chengappa

Published: June 1, 2003

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Bipolar disorder is an episodic psychiatric illness requiring lifelong treatment. As agroup of illnesses, bipolar disorder has a prevalence rate of 1.2% to 3.4%1 in the general population, a rate that is half as much as type 2 diabetes mellitus, and yet it is the sixthmost disabling medical condition.2 For the fortunate patient with a lithium-responsive biology,life reverts to near normal, but for somewhere between one third to two thirds of bipolarsubjects, alternatives to or adjunctive treatment with lithium is needed, especially in themaintenance phase.’ ‹


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 64

Quick Links: Bipolar Disorder

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Frontothalamic Circuit Abnormalities in Patients With Bipolar Depression and Suicide Attempts

To identify potential markers for suicide risk, this fMRI study looked at neural activity in bipolar depression...

Read More...